In November 2013 and August 2014, Apomivir® was approved to proceed the clinical trial (IND) by US FDA and Taiwan FDA respectively on treatment and alleviate Influenza associated syndrome. Apomivir® could directly enter phase II trial to evaluate the efficacy in human with no bio-safety concern. In preclinical study, Apomivir® had been proven to have excellent broad-spectrum anti-flu ability, and also include the Oseltamivir-resistant, new pandemic and H7N9 influenza viruses.
The broad enterovirus species prevalent in China, Taiwan, and ASEAN is a big public health issues to the young children below age of 5. Recently, the climate change also cause prevalence of enteroviruses in temperate countries. FEBICO has demonstrated that FB998 has broad spectrum inhibition effects against enteroviruses, and relieves clinical symptoms of enterovirus in animal models. In the meantime, FEBICO collaborates with multiple academic centers to investigate the mechanisms of anti-enterovirus effects for further candidate and formulation optimization.
Respiratory tract infectious diseases induced by respiratory syncytial virus species have been the main reason of hospitalization in newborns and elders. However, the drugs until now are still very expensive and limited effective to be applied and popularized. FB301 could significantly inhibit several respiratory associated virus species. FEBICO collaborates with multiple academic centers to investigate the anti-viral mechanisms, devoted to optimizing drugs formulation.